Ultime notizie per INmune Bio (NASDAQ:INMB) Azioni

INmune Bio

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

INmune Bio Inc

Biotech

News

General

INMB

INmune Bio Completed Randomization Of Patients For Its Phase 2 Trial

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.50) by 20 percent. This is a 25 percent decrease over losses of $(0.48) per share from the same period last year.

Earnings

Earnings Misses

INmune Bio Q3 EPS $(0.60) Misses $(0.50) Estimate

WIIM

INmune Bio shares are trading higher after the company announced it will host a webinar on cognitive testing using EMACC and CDR-SB on November 7 at 1 pm ET.

"Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials" Webinar to be Held on November 7, 2024, at 1 PM ET.
Poster on EMACC Sensitivity and Performance in Phase II Alzheimer's Trial to be Presented at CTAD2024
Boca Raton, Florida, Oct. 28, 2024 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=6s8KWaUzAwqubvNXKfWRdgyHHbqBhVyfHJuyW2HkHSNoFa2__Lm6gWqUINuxzs0KK6qhQzBtvLHEcHq0vp1iO8QYJzIbce0azdw7XTvSh0EBwPYhbfQrIR_r9wSdWmsVGCVG-V7FrekEFnohTpCzOkrtbKbg9f_0tvreLsuK8LZfFQtPccUeGW4GfP2VImcfDt-eFV0sABvddjYTuYBz6Go9R7hmD-_na6mBStMbeBGsVVR46Z5tNyPOk5ypMw3tcZeCkKrA6Kr7QS6zONKwSSdfIJiIo17LdwuIvEtVeHj6389KI4mQ3AvW7hN3OFmpa5yF1U3T1NGuD_EyrDEnB2Nc9tTsSyOrlHpRVhyX-tK22-xBxHcXJxjEBzpEGfObOaBdUnnn6YEbFsPZz4DBCBmHnZUbSJhhA60Y-YG61ZqTcqi8baXLoedBKNAQ0ExAz-_Hf1r_Qq4A97ovJVHIKA==">INmune Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease is hosting a Webinar on November 7, 2024 at 1 PM ET.
The webinar, titled "Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials," will explore the development of EMACC and its advantages in assessing cognitive changes over time in early Alzheimer's Disease (AD) patients. It will also cover the regulatory landscape for Alzheimer's disease drug development and the role of the CDR-SB clinical scale. Speakers include Dr. Judith Jaeger, President of CognitionMetrics and leader of the team that developed and validated EMACC, Dr. Sarah Barnum, and CJ Barnum, VP of CNS Drug Development at INmune Bio.

INmune Bio Inc. To Host Webinar On Cognitive Testing Using EMACC And CDR-SB On November 7, 2024, At 1 PM ET

Data from Animal Model Study Demonstrate XPro&#x2122; converts microglia from a demyelinating cell to a remyelinating cell &nbsp;
Multi-year study published has implications for many CNS diseases including Alzheimer's
Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=7tPZlwv14diVgOj9zG2t9UjV6ed0y__rf2yOtS4-8WgTVbHzna772LgK5h1hUWFNmPJqpjI6DNnNhcbkAcfvKWUppwKIenbogc-v_UsvWa4=">INmune Bio, Inc.</a>&nbsp;(NASDAQ:<a href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announces the publication of a seminal paper in the journal Cell Reports that demonstrates XPro1595 promotes remyelination in an animal model of demyelinating disease. The study, <a href="https://www.globenewswire.com/Tracker?data=Y256I8uMswP5hrKqLX5SJfQyiGYsFtnr7mmHRU10GuUytoNjX1jBIFQCoe0NW4KVtpTJ_dmm-iRjwiRtsIKetlOk3hBzuFs2LVG9dnVJK6JRPShLBU0a7uclGufquuie0njmAsvcXuj12EakN82oZui7WnWHKgeh18hWOrI1NoH6BnwLOaTUPfvyGtDd2YPWAxwsiKJksUGytS4SuUhM04qFBCKJaT67AFGAUU7z85E-7q3knP4t9jnOiegOc18rCXi76Q8bdGrif-FbHs5KhvqPn2_9o2aa9W8rvw8YeGU=">Microglia Regulate Cortical Remyelination via ΤNFR1-Dependent Phenotypic Polarization</a>, was performed under the direction of Leslie Probert PhD, Head of Immunology at the Hellenic Pasteur Institute in Athens Greece, and is the culmination of several years of work supported by EU research grants.
Myelin is necessary for fast and efficient communication between neurons. Loss of myelin compromises neuron function and communication and is a key step in the neurodegenerative process of many CNS diseases, including Alzheimer's Disease.

INmune Bio Announces Publication In Cell Reports That Demonstrates XPro1595 Promotes Remyelination In An Animal Model Of Demyelinating Disease

Alliance Global Partners analyst James Molloy initiates coverage on INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) with a Buy rating and announces Price Target of $20.

Price Target

Initiation

Analyst Ratings

Alliance Global Partners Initiates Coverage On INmune Bio with Buy Rating, Announces Price Target of $20

INmune Bio Inc. Completes Enrollment For Phase 2 Trial In Early Alzheimer's Disease

Raymond James initiates coverage on INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) with a Outperform rating and announces Price Target of $18.

Raymond James Initiates Coverage On INmune Bio with Outperform Rating, Announces Price Target of $18

INmune Bio shares are trading higher after the company announced its INKmune Phase I/II trial for metastatic castration-resistant prostate cancer (mCRPC) demonstrated excellent safety and increased NK-cell activity in the first dosing cohort.

INmune Bio's INKmune Demonstrates Excellent Safety And Increased NK-Cell Activity In First Dosing Cohort Of Phase I/II Trial For Metastatic Castration-Resistant Prostate Cancer (mCRPC)

INmune Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease (AD) trial demonstrated &nbsp;exceptional performance of the novel cognitive measure EMACC, as well as highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the accepted endpoint for AD trials. &nbsp;

INmune Bio Announces Results Of Additional Blinded Interim Analysis Of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation Between EMACC And CDR-SB Endpoints

Inmune Bio shares are trading lower after the company announced a $13 million registered direct offering of 2,341,260 shares.

INmune Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company" or "INmune Bio"), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced&nbsp;it has entered into securities purchase agreements with new and existing institutional investors and certain directors and officers and employees of the Company (the directors and officers and employees herein referred to as the "Insiders"), for the purchase and sale of 2,341,260 shares of its common stock and warrants to purchase up to an aggregate of 2,341,260 shares of common stock at a combined purchase price per share and accompanying warrant of $5.50 for the institutional investors, and $6.50 per share and accompanying warrant for the Insiders, pursuant to a registered direct offering. The warrants will be exercisable commencing six months from the date of issuance at a price of $6.40 per share and will expire five years from the initial exercise date. The warrant term may be subject to acceleration following the satisfaction of certain conditions. In the case of Insiders that participated in the offering, if the warrant termination date is on a blackout date, then the Insiders will have an additional 60 days from the termination of the blackout date to exercise the warrant.
The gross proceeds of the offering will be approximately $13.0 million before deducting placement agent fees and other estimated offering expenses. The closing of the offering is expected to take place on or about September 16, 2024, subject to the satisfaction of customary closing conditions.&nbsp;The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

Offerings

INmune Bio Announces $13M Registered Direct Offering

Scotiabank analyst George Farmer initiates coverage on INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) with a Sector Outperform rating and announces Price Target of $22.

Scotiabank Initiates Coverage On INmune Bio with Sector Outperform Rating, Announces Price Target of $22

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.63) by 20.63 percent. This is a 38.89 percent decrease over losses of $(0.36) per share from the same period last year.

Earnings Beats

INmune Bio Q2 2024 GAAP EPS $(0.50) Beats $(0.63) Estimate

AAIC Poster Presentation Highlights XPro's&#x2122; Significant Effects on a Wide Range of Synaptic Proteins and Pathways
BOCA RATON, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=Eq2O4sfQJqc5he9r4GnP2Yokfr2xxbsPCcZ1gBdJ33ioSAKSCHOBiGgLCQF3qc0-x5XpB9n84vmX42BWK-OuD2EIJXbacrDI5TA_7j7WM8bGpE228AvJK4VBghWisvzQyLt9VSiulyt4HEL8K9I2MjbiCKvtebUtZP6rsba_E4LiCTLcT1NPjlALlLPmrWW02Byl6Q19WYoKPtmwM2Th8_1xJ3Ez3IXbYBKaA7u01bFK3GeB2tanhFhVnqvq-Tj8">INmune Bio Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease is pleased to be presenting results of a new and advanced proteomic analysis at this year's annual Alzheimer's Association International Conference (AAIC) in Philadelphia, PA. The poster summarizes dose-related changes in the cerebrospinal fluid (CSF) proteome in patients with Alzheimer's disease (AD) treated with XProTM in the company's phase 1b study.

INmune Bio Presents New Phase 1 Study Data Demonstrating Dose-Dependent Effect Of XPro On Proteins That Regulation Synapses In Alzheimer's Patients In AAIC Poster Presentation

<a href="https://jitc.bmj.com/content/12/7/e008717" title="https://jitc.bmj.com/content/12/7/e008717">https://jitc.bmj.com/content/12/7/e008717</a>

INmune Highlights Publication Titled 'Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy'

INmune Bio Completes Blinded Interim Analysis Of Its Phase II Alzheimer's Disease Trial, Says 'The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint.'

<h3>Gainers</h3>
<ul>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares rose 32.8% to $3.79 during Thursday's pre-market session. The company's market cap stands at $84.0 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares rose 31.92% to $40.0. The company's market cap stands at $519.2 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares rose 28.94% to $2.45. The company's market cap stands at $6.1 million. </li>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) stock moved upwards by 24.03% to $3.2. The market value of their outstanding shares is at $29.5 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock rose 23.33% to $0.44. The market value of their outstanding shares is at $8.0 million. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock rose 22.23% to $9.73. The company's market cap stands at $322.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock fell 27.4% to $0.62 during Thursday's pre-market session. The market value of their outstanding shares is at $17.4 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares declined by 9.25% to $1.32. The market value of their outstanding shares is at $45.0 million. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock decreased by 9.05% to $2.01. The market value of their outstanding shares is at $5.0 million. </li>
<li>INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) shares declined by 8.97% to $7.01. The company's market cap stands at $138.6 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock fell 8.92% to $2.2. The market value of their outstanding shares is at $1.8 million. </li>
<li>Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) shares decreased by 8.65% to $34.43. The market value of their outstanding shares is at $589.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CNSP

CYCN

GOVX

MBIO

MNDR

MOLN

NGNE

PRAX

SABS

Tempest Therapeutics, Inc. - Common Stock

TPST

TRVN

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<a href="https://www.globenewswire.com/Tracker?data=GRd7EqCrOP6sn85ZgV1i_a8iRH7MQcRH48vM_oAFHr5TCkQr5CFPa37kZuABSjRpy5CPCOJBJrHnZdGLFk0dMeTcQ_5_wQJL11fXGpID1ChYsaIfnp4yyYROG77fvEoGubj4QCJS03jVmJfLzYbcKuBv2bkJUFD2LIbyJiPtAfhFYLe_Qxe0dYUhi_EJztFdIxEFXQbrfgccphqJl_0Qc0f9SpqNXybovbOKI_PTEasCvqVrvIXt9v-Od-oakOvrqg8GcuF8vzejEr-zYneXBuuGAz0S89YfsrdQBTMDouq-QT12FkiNV2SKfJ7OAX90WCM_66vswU3m5orwI1_jIcEoiWrm9KN9ZMNSzUHf_M02FRrsckLYaH5sQfEmQlOvFFLVp9Ee7iaujNcoGt347IHXon0fPNZ4WYTfZv48arZk5QcLrVAZBfk-67-TbW_QQJXI5qo-Ul5qe2bQ7gRtrnVakZkClgtr6O7JZQ2LXyPv-p2gcqFFSOuxh398BbkMQ-mgn4XrCYeNHn8ecozy55bj_jmlY0mL3F9py-bxXN_3ozi4m61voQbtU7BQko7oT8O_M0ZdNTrqMw6EfsayTfAdhG7fmV8H2OIBleJ4090N_4GAZ8HOC2G3qNSH_7eyRpY2Z6rTwlPp38JA5Yuq7SAmnjJK7gt-InRowRZrnj5Td-lAbkTT5Vufgu5lmVncd2Oo3fld-HwIBREV3MdP5XwT4rtv_ihf4FRw5pNajuY=">INmune Bio Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000&#xAE;&nbsp;Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.

INmune Bio To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1

INmune Bio (INMB) announced the publication of a seminal paper in the journal Cell Reports that demonstrates XPro1595 promotes remyelination in an ...

INmune Bio announces publication of XPro1595 data in Cell Reports

INmune Bio (INMB) is hosting a Webinar on November 7, 2024. The webinar, titled "Why EMACC is the Optimal Tool for Measuring Cognitive Change in Ea...

INmune Bio to host webinar on cognitive testing using EMACC, CDR-SB

INmune Bio Q3 2024 Earnings Preview

INmune Bio GAAP EPS of -$0.60 misses by $0.10

INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript

Warning: INMB is at high risk of performing badly

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Inmune Bio (INMB – Research Report). The associated price target remains ...

Inmune Bio's Promising Pipeline and Financial Stability Justify Buy Rating

Management holds an Analyst and Investor Webinar on Cognitive Testing using EMACC and CDR-SB on November 7 at 1 pm. Webcast Link Published first on...

INmune Bio holds an investor and analyst webinar

INmune Bio (INMB) announced that it completed randomization of patients for its Phase 2 trial on Monday, November 11th. This global, blinded, rando...

INmune Bio announces enrollment of 208 patients in Phase 2 trial of early AD

Inmune Bio's Innovative Alzheimer's Treatment Approach Earns 'Buy' Rating from Analyst

Press Releases

INmune Bio Announces $13.0 Million Registered Direct Offering

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

Comments

INmune Bio

Notizie

Ultime notizie per INmune Bio (NASDAQ:INMB) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO